CDK9 and neoplasm: BAY1143572 (atuveciclib), the first highly selective CDK9 inhibitor described by Bayer, exhibited marked tumour growth inhibition in preclinical models of acute myeloid leukaemia [75] and adult T-cell leukaemia/lymphoma [76].